Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Jessen

Showing results (41-50 of 538) with videos related to

Pageof 54
Sort By:
Alzheimer'S Research & Therapy|January 28, 2023
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trialGlen Wunderlich, Zuzana Blahova, Miguel Garcia, et al.
The American Journal of Drug and Alcohol Abuse|January 12, 2019
Neuronal correlates of delay discounting in healthy subjects and its implication for addiction: an ALE meta-analysis studyCanan Beate Schüller, Jens Kuhn, Frank Jessen, et al.
Ageing Research Reviews|November 6, 2021
Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic reviewChristiane Oedekoven, Leonie Egeri, Frank Jessen, et al.
Neurology|August 26, 2022
Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysisAyda Rostamzadeh, Lara Bohr, Michael Wagner, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 19, 2014
N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: a systematic reviewGeorgios Paslakis, Frank Träber, Jens Roberz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2009
Treatment of hypersexuality in Parkinson's disease with carbamazepine--a case reportJan-Philipp Bach, Wolfgang H Oertel, Richard Dodel, et al.
Lancet (London, England)|November 17, 2024
Amyloid-lowering treatment in Alzheimer's diseaseFrank Jessen, Lutz Frölich, Jakub Hort, et al.
Dementia and Geriatric Cognitive Disorders|June 24, 2004
Contribution of apolipoprotein E and cathepsin D genotypes to the familial aggregation of Alzheimer's diseaseReinhard Heun, Ursula Ptok, Heike Kölsch, et al.
Journal of Neurology|March 16, 2007
Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subjectJulius Popp, Dietmar R Thal, Piotr Lewczuk, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive DeclineOctavio Rodríguez-Gómez, Carla Abdelnour, Frank Jessen, et al.
Pageof 54

Showing results (41-50 of 538) with videos related to

Sort By:
Pageof 54
Alzheimer'S Research & Therapy|January 28, 2023
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trialGlen Wunderlich, Zuzana Blahova, Miguel Garcia, et al.
The American Journal of Drug and Alcohol Abuse|January 12, 2019
Neuronal correlates of delay discounting in healthy subjects and its implication for addiction: an ALE meta-analysis studyCanan Beate Schüller, Jens Kuhn, Frank Jessen, et al.
Ageing Research Reviews|November 6, 2021
Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic reviewChristiane Oedekoven, Leonie Egeri, Frank Jessen, et al.
Neurology|August 26, 2022
Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysisAyda Rostamzadeh, Lara Bohr, Michael Wagner, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 19, 2014
N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: a systematic reviewGeorgios Paslakis, Frank Träber, Jens Roberz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2009
Treatment of hypersexuality in Parkinson's disease with carbamazepine--a case reportJan-Philipp Bach, Wolfgang H Oertel, Richard Dodel, et al.
Lancet (London, England)|November 17, 2024
Amyloid-lowering treatment in Alzheimer's diseaseFrank Jessen, Lutz Frölich, Jakub Hort, et al.
Dementia and Geriatric Cognitive Disorders|June 24, 2004
Contribution of apolipoprotein E and cathepsin D genotypes to the familial aggregation of Alzheimer's diseaseReinhard Heun, Ursula Ptok, Heike Kölsch, et al.
Journal of Neurology|March 16, 2007
Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subjectJulius Popp, Dietmar R Thal, Piotr Lewczuk, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive DeclineOctavio Rodríguez-Gómez, Carla Abdelnour, Frank Jessen, et al.
Pageof 54